Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS

Cancer Cell

Volumn 26, Issue 4, 2014, Pages 509-520

  Schneider, RebekkaK ^a   Ademà, Vera ^b,c   Heckl, Dirk ^a   Järås, Marcus ^a   Mallo, Mar ^b,c   Lord, AllegraM ^a   Chu, LisaP ^a   McConkey, MarieE ^a   Kramann, Rafael ^d   Mullally, Ann ^a   Bejar, Rafael ^e   Solé, Francesc ^b,c   Ebert, BenjaminL ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASEIN KINASE 1A1; CASEIN KINASE IALPHA; CD11B ANTIGEN; CD19 ANTIGEN; CYCLIN D1; FIBRINOGEN RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG; CASEIN KINASE I; PRIMER DNA;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CHROMOSOME 5Q; CONTROLLED STUDY; DEL(5Q) MYELODYSPLASTIC SYNDROME; ENZYME INACTIVATION; EXON; GENE EXPRESSION; GENE MUTATION; HAPLOINSUFFICIENCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HETEROZYGOTE; LEUKOCYTE COUNT; LYMPHOCYTOSIS; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN FUNCTION; SOMATIC MUTATION; STEM CELL EXPANSION; STROMA CELL; AGED; ANIMAL; CHROMOSOME 5; CHROMOSOME DELETION; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; POLYMERASE CHAIN REACTION; YOUNG ADULT;

AGED; ANIMALS; BASE SEQUENCE; CASEIN KINASE I; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; HAPLOINSUFFICIENCY; HUMANS; MALE; MICE; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84908006668     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.08.001     Document Type: Article

References (51)

1. Albuquerque C., Breukel C., van der Luijt R., Fidalgo P., Lage P., Slors F.J., Leitão C.N., Fodde R., Smits R. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum. Mol. Genet. 2002, 11:1549-1560.
2. Baba Y., Garrett K.P., Kincade P.W. Constitutively active beta-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors. Immunity 2005, 23:599-609.
3. Bidère N., Ngo V.N., Lee J., Collins C., Zheng L., Wan F., Davis R.E., Lenz G., Anderson D.E., Arnoult D., et al. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature 2009, 458:92-96.
4. Boultwood J., Pellagatti A., Cattan H., Lawrie C.H., Giagounidis A., Malcovati L., Della Porta M.G., Jädersten M., Killick S., Fidler C., et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br. J. Haematol. 2007, 139:578-589.
5. Boultwood J., Pellagatti A., McKenzie A.N., Wainscoat J.S. Advances in the 5q- syndrome. Blood 2010, 116:5803-5811.
6. Chen T.H., Kambal A., Krysiak K., Walshauser M.A., Raju G., Tibbitts J.F., Walter M.J. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood 2011, 117:1530-1539.
7. Cheong J.K., Virshup D.M. Casein kinase 1: Complexity in the family. Int. J. Biochem. Cell Biol. 2011, 43:465-469.
8. Davidson G., Wu W., Shen J., Bilic J., Fenger U., Stannek P., Glinka A., Niehrs C. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005, 438:867-872.
9. Dulak A.M., Stojanov P., Peng S., Lawrence M.S., Fox C., Stewart C., Bandla S., Imamura Y., Schumacher S.E., Shefler E., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 2013, 45:478-486.
10. Dutt S., Narla A., Lin K., Mullally A., Abayasekara N., Megerdichian C., Wilson F.H., Currie T., Khanna-Gupta A., Berliner N., et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011, 117:2567-2576.
11. Ebert B.L. Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin. Oncol. 2011, 38:621-626.
12. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R., Golub T.R. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
13. Elyada E., Pribluda A., Goldstein R.E., Morgenstern Y., Brachya G., Cojocaru G., Snir-Alkalay I., Burstain I., Haffner-Krausz R., Jung S., et al. CKIα ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470:409-413.
14. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
15. Graubert T.A., Payton M.A., Shao J., Walgren R.A., Monahan R.S., Frater J.L., Walshauser M.A., Martin M.G., Kasai Y., Walter M.J. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS ONE 2009, 4:e4583.
16. Graubert T.A., Shen D., Ding L., Okeyo-Owuor T., Lunn C.L., Shao J., Krysiak K., Harris C.C., Koboldt D.C., Larson D.E., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 2012, 44:53-57.
17. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., Kundgen A., Lübbert M., Kunzmann R., Giagounidis A.A., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
18. Hasserjian R.P., LeBeau M.M., List A.F., Bennett J.M., Thiele J. Myelodysplastic syndrome with isolated del(5q). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 102. WHO Press, Geneva, Switzerland. Fourth edition. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
19. Heinrichs S., Kulkarni R.V., Bueso-Ramos C.E., Levine R.L., Loh M.L., Li C., Neuberg D., Kornblau S.M., Issa J.P., Gilliland D.G., et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 2009, 23:1605-1613.
20. Järås M., Miller P.G., Chu L.P., Puram R.V., Fink E.C., Schneider R.K., Al-Shahrour F., Peña P., Breyfogle L.J., Hartwell K.A., et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J.Exp. Med. 2014, 211:605-612.
21. Jerez A., Gondek L.P., Jankowska A.M., Makishima H., Przychodzen B., Tiu R.V., O'Keefe C.L., Mohamedali A.M., Batista D., Sekeres M.A., et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J.Clin. Oncol. 2012, 30:1343-1349.
22. Joslin J.M., Fernald A.A., Tennant T.R., Davis E.M., Kogan S.C., Anastasi J., Crispino J.D., Le Beau M.M. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007, 110:719-726.
23. Kirstetter P., Anderson K., Porse B.T., Jacobsen S.E., Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat. Immunol. 2006, 7:1048-1056.
24. Koboldt D.C., Zhang Q., Larson D.E., Shen D., McLellan M.D., Lin L., Miller C.A., Mardis E.R., Ding L., Wilson R.K. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012, 22:568-576.
25. Kode A., Manavalan J.S., Mosialou I., Bhagat G., Rathinam C.V., Luo N., Khiabanian H., Lee A., Murty V.V., Friedman R., et al. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 2014, 506:240-244.
26. Kumar M.S., Narla A., Nonami A., Mullally A., Dimitrova N., Ball B., McAuley J.R., Poveromo L., Kutok J.L., Galili N., et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011, 118:4666-4673.
27. Lane S.W., Sykes S.M., Al-Shahrour F., Shterental S., Paktinat M., Lo Celso C., Jesneck J.L., Ebert B.L., Williams D.A., Gilliland D.G. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood 2010, 115:3489-3497.
28. Luis T.C., Naber B.A., Roozen P.P., Brugman M.H., de Haas E.F., Ghazvini M., Fibbe W.E., van Dongen J.J., Fodde R., Staal F.J. Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell 2011, 9:345-356.
29. Luis T.C., Ichii M., Brugman M.H., Kincade P., Staal F.J. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia 2012, 26:414-421.
30. Mallo M., Del Rey M., Ibáñez M., Calasanz M.J., Arenillas L., Larráyoz M.J., Pedro C., Jerez A., Maciejewski J., Costa D., et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br. J. Haematol. 2013, 162:74-86.
31. McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010, 20:1297-1303.
32. Miller P.G., Al-Shahrour F., Hartwell K.A., Chu L.P., Järås M., Puram R.V., Puissant A., Callahan K.P., Ashton J., McConkey M.E., et al. InVivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 2013, 24:45-58.
33. Min I.M., Pietramaggiori G., Kim F.S., Passegué E., Stevenson K.E., Wagers A.J. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2008, 2:380-391.
34. Nijhawan D., Zack T.I., Ren Y., Strickland M.R., Lamothe R., Schumacher S.E., Tsherniak A., Besche H.C., Rosenbluh J., Shehata S., et al. Cancer vulnerabilities unveiled by genomic loss. Cell 2012, 150:842-854.
35. Peters J.M., McKay R.M., McKay J.P., Graff J.M. Casein kinase I transduces Wnt signals. Nature 1999, 401:345-350.
36. Rena G., Bain J., Elliott M., Cohen P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004, 5:60-65.
37. Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013, 45:860-867.
38. Scheller M., Huelsken J., Rosenbauer F., Taketo M.M., Birchmeier W., Tenen D.G., Leutz A. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat. Immunol. 2006, 7:1037-1047.
39. Sinnberg T., Menzel M., Kaesler S., Biedermann T., Sauer B., Nahnsen S., Schwarz M., Garbe C., Schittek B. Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. Cancer Res. 2010, 70:6999-7009.
40. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., Hirst M., Hogge D., Marra M., Wells R.A., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 2010, 16:49-58.
41. Stoddart A., Fernald A.A., Wang J., Davis E.M., Karrison T., Anastasi J., Le Beau M.M. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood 2014, 123:1069-1078.
42. Trowbridge J.J., Xenocostas A., Moon R.T., Bhatia M. Glycogen synthase kinase-3 is an invivo regulator of hematopoietic stem cell repopulation. Nat. Med. 2006, 12:89-98.
43. Walkley C.R., Olsen G.H., Dworkin S., Fabb S.A., Swann J., McArthur G.A., Westmoreland S.V., Chambon P., Scadden D.T., Purton L.E. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129:1097-1110.
44. Wang J., Fernald A.A., Anastasi J., Le Beau M.M., Qian Z. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood 2010, 115:3481-3488.
45. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., Zon L.I., Armstrong S.A. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
46. Willert K., Brown J.D., Danenberg E., Duncan A.W., Weissman I.L., Reya T., Yates J.R., Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003, 423:448-452.
47. Woll P.S., Kjällquist U., Chowdhury O., Doolittle H., Wedge D.C., Thongjuea S., Erlandsson R., Ngara M., Anderson K., Deng Q., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells invivo. Cancer Cell 2014, 25:794-808.
48. Wu S., Chen L., Becker A., Schonbrunn E., Chen J. Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol. Cell. Biol. 2012, 32:4821-4832.
49. Xu J., Suzuki M., Niwa Y., Hiraga J., Nagasaka T., Ito M., Nakamura S., Tomita A., Abe A., Kiyoi H., et al. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br. J. Haematol. 2008, 140:394-401.
50. Yeung J., Esposito M.T., Gandillet A., Zeisig B.B., Griessinger E., Bonnet D., So C.W. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010, 18:606-618.
51. Zhu H., Guo Z.K., Jiang X.X., Li H., Wang X.Y., Yao H.Y., Zhang Y., Mao N. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat. Protoc. 2010, 5:550-560.